Key Points
- Insider Eric Warren sold 7,438 Mineralys Therapeutics shares at an average price of $28.12, generating $209,156.56. The Rule 10b5-1 transaction reduced his holdings by 16.23% to 38,400 shares.
- MLYS opened at $29.40, with a market capitalization of approximately $2.60 billion. The company recently reported a quarterly loss of $2.85 per share, significantly wider than the $0.55-per-share consensus estimate.
- Analyst sentiment remains mixed but leans positive, with a consensus rating of “Moderate Buy” and an average price target of $48.80; institutional investors own 84.46% of the stock.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider Eric Warren sold 7,438 shares of the stock in a transaction on Monday, September 21st. The shares were sold at an average price of $28.12, for a total transaction of $209,156.56. Following the completion of the sale, the insider directly owned 38,400 shares of the company's stock, valued at approximately $1,079,808. This trade represents a 16.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Warren also recently made the following trade(s):
- On Friday, August 21st, Eric Warren sold 7,437 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.98, for a total transaction of $193,213.26.
- On Tuesday, July 21st, Eric Warren sold 7,438 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.87, for a total transaction of $199,859.06.
- On Friday, June 26th, Eric Warren sold 104,124 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.90, for a total transaction of $2,696,811.60.
Mineralys Therapeutics Stock Up 3.9%
MLYS stock opened at $29.40 on Wednesday. Mineralys Therapeutics, Inc. has a twelve month low of $22.30 and a twelve month high of $47.65. The company has a quick ratio of 34.46, a current ratio of 34.46 and a debt-to-equity ratio of 0.18. The company has a market cap of $2.60 billion, a PE ratio of -6.93 and a beta of 0.68. The business's 50-day simple moving average is $27.18 and its 200 day simple moving average is $27.10.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.30). On average, research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.45 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on MLYS shares. Jefferies Financial Group reiterated a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Zacks Research raised shares of Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, September 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. HC Wainwright reissued a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Finally, Wall Street Zen lowered shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Mineralys Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.80.
Get Our Latest Stock Analysis on Mineralys Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Timothy G. Youngquist 2020 Irrevocable Trust acquired a new position in shares of Mineralys Therapeutics in the 2nd quarter worth approximately $2,721,000. TimesSquare Capital Management LLC acquired a new stake in Mineralys Therapeutics during the 2nd quarter valued at $6,363,000. Bank of America Corp DE increased its holdings in Mineralys Therapeutics by 11.5% during the 1st quarter. Bank of America Corp DE now owns 1,100,372 shares of the company's stock valued at $29,809,000 after purchasing an additional 113,092 shares in the last quarter. Man Group plc bought a new position in Mineralys Therapeutics in the 2nd quarter valued at $1,609,000. Finally, Artia Global Partners LP boosted its stake in Mineralys Therapeutics by 143.5% in the fourth quarter. Artia Global Partners LP now owns 137,800 shares of the company's stock worth $5,001,000 after purchasing an additional 81,200 shares in the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company's research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.
Mineralys' lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
